Benzinga

Benzinga

Benzinga

martes, septiembre 01

Recursion Pharmaceuticals Inc

RXRXNASDAQ
Trade with Public
Trade with Public
$3.35
-0.045-1.32%
Últ. Act.: Sep 1, 10:56 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Recursion Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Recursion Pharmaceuticals (RXRX).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

3Buy
4Hold
Consensus RatingOverweight# Analysts7Avg. Consensus PT$8Upside to Avg. PT+132.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 14, 2026Morgan StanleyVikram PurohitPT RaiseEqual-Weight$5→$6
May 7, 2026NeedhamGil BlumMaintainedBuy$8
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Equal-Weight and raises the price target from $5 to $5.5.
Benzinga Newsdesk

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.
Priya Nigam

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $11 to $10.
Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

B of A Securities analyst Michael Ryskin maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Neutral and lowers the price target from $7 to $6.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved